Sanofi-Aventis' DolipraneLib and Burgopak Honored in France

Sanofi-Aventis' DolipraneLib has been recognized in the "Family Medicine" category in France's ImpactPharmacien awards. Burgopak Healthcare & Technology's patented sliding mechanism presents the product and its vital information to the user immediately upon opening.

"DolipraneLib is the OTC brand of Doliprane. Doliprane, in its 60 years, has always been close to the consumers," stated Isabelle Senges, product manager at Doliprane, Sanofi-Aventis, in a press release. "We have launched a wide variety of dosages. DolipraneLib is a turning point in the products history with how we have innovated in terms of packaging. The slider opening system is very original and very modern. For us it is very important to receive this award as a recognition of a change in our innovations."

Burgopak offers its package to ease product use, which could include improving patient compliance, among other endeavors. "The Burgopak slider design offers a revolutionary and innovative way to deliver product in the highly competitive OTC market," said Tim Clarke, CEO of Burgopak, in a press release. "To be chosen by Sanofi Aventis to launch such a historical consumer brand in the Burgopak slider was a huge honour. Winning this award is recognition that the Burgopak slider design adds significant value to the brand, the pharmacy industry and their consumers."

DolipraneLib OTC paracetamol product became available in French pharmacies at the end of 2010. For further information on IMPACT PHARMACIEN please visit their website: www.impact-sante.fr

Back to Home